[Refractional results of LASIK retreatment with wavefront-guided ablation versus standard ablation].
OBJECTIVE
To evaluate refractive outcomes of wavefront-guided LASIK (Zyoptix, Bausch & Lomb) versus standard LASIK (PlanoScan, Bausch & Lomb) in retreatment of primary LASIK for myopia and myopic astigmatism.


METHODS
A prospective, randomized trial with paired eye control of 74 eyes from 37 patients who underwent LASIK retreatment was performed. Each patient underwent retreatment using Zyoptix LASIK in 1 eye and Planoscan LASIK in the contralateral eye. A complete ophthalmologic examination was performed, including evaluation of high contrast visual acuity and manifest refraction, with a follow-up of 6 months.


RESULTS
Both Zyoptix and Planoscan groups had similar values of high contrast visual acuity, gain and loss of best spectacle-corrected visual acuity, safety and efficacy indexes, percentage of eyes with spherical equivalent within +/- 0,50 D and +/- 1,00 D in the postoperative period of 6 months. In the Zyoptix group, the values of spherical component and spherical equivalent of manifest refraction were more hyperopic than in the Planoscan group in the postoperative periods of 1 week, 1, 3 and 6 months. The predictability of spherical equivalent correction was better for the Zyoptix group than for the Planoscan group at 6 months.


CONCLUSIONS
Wavefront-guided LASIK with Zyoptix produces superior refractive outcomes than standard LASIK with Planoscan in retreatment of refractive errors after primary LASIK. High contrast visual acuity measures are not sensitive in showing the best technique.
Urbano
Andréia Peltier
AP
Oftalmologia e Ciências Visuais, Universidade Federal de São Paulo, São Paulo, Brasil. andreiaurbano@terra.com.br
Nosé
Walton
W
D000328:Adult; D001251:Astigmatism / Q000601:surgery*; D005260:Female; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery*; D011446:Prospective Studies; D012086:Reoperation; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult